U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C15H13NO3S2.C15H12NO3S2.C5H14NO
Molecular Weight 741.96
Optical Activity NONE
Defined Stereocenters 0 / 1
E/Z Centers 4
Charge 0

SHOW SMILES / InChI
Structure of DIEPALRESTAT CHOLINE

SMILES

C[N+](C)(C)CCO.CC(=C/C1=CC=CC=C1)\C=C2/SC(=S)N(CC(O)=O)C2=O.CC(=C/C3=CC=CC=C3)\C=C4/SC(=S)N(CC([O-])=O)C4=O

InChI

InChIKey=WKSNHZZSMLFYFI-UROVXFGGSA-M
InChI=1S/2C15H13NO3S2.C5H14NO/c2*1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12;1-6(2,3)4-5-7/h2*2-8H,9H2,1H3,(H,17,18);7H,4-5H2,1-3H3/q;;+1/p-1/b2*10-7+,12-8-;

HIDE SMILES / InChI

Molecular Formula C15H13NO3S2
Molecular Weight 319.399
Charge 0
Count
MOL RATIO 2 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 2
Optical Activity NONE

Molecular Formula C5H13NO
Molecular Weight 103.1628
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity NONE

Description

Epalrestat is an aldose reductase inhibitor that is approved in Japan for the improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal changes in heart beat associated with diabetic peripheral neuropathy.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.28 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
KINEDAK

Cmax

ValueDoseCo-administeredAnalytePopulation
3.9 μg/mL
50 mg single, oral
EPALRESTAT plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
6.4 μg × h/mL
50 mg single, oral
EPALRESTAT plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
9.9%
50 mg single, oral
EPALRESTAT plasma
Homo sapiens

Doses

AEs

PubMed

Sample Use Guides

In Vivo Use Guide
50 mg, 3 times/day
Route of Administration: Oral
In Vitro Use Guide
Human umbilical vein endothelial cells were cultured for 48 h in glucose-rich (27.8 mM) medium. The increased neutrophil-endothelial cell adhesion and surface expression of intercellular adhesion molecule-1 (ICAM-1), P-selectin, and E-selectin on endothelial cells was inhibited by 10 microM of epalrestat.
Substance Class Chemical
Record UNII
16AHE7410O
Record Status Validated (UNII)
Record Version